Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation.

Next Previous
X
Search
Trial Profile

The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms TEAM
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 06 Mar 2017 Results published in the Annals of Oncology
    • 25 Nov 2015 Protocol has been amended to change in treatment arm from one arm to two arm study, as per ClinicalTrials.gov record.
    • 18 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top